Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
April 19 2023 - 11:10AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the
month of April 2023
Commission File
Number 001-15170
GSK
plc
(Translation of
registrant's name into English)
980
Great West Road, Brentford, Middlesex, TW8 9GS
(Address of
principal executive office)
Indicate by check
mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): ____
GSK plc (the 'Company')
Transaction
notification
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Ms
E Walmsley
|
|
b)
|
Position/status
|
Chief
Executive Officer
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 13 April 2023 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.2240
|
456
|
|
£15.2240
|
682
|
|
£15.2240
|
1,133
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume
Price
|
2,271
£15.2240
|
|
e)
|
Date
of the transaction
|
2023-04-17
|
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr
I Mackay
|
|
b)
|
Position/status
|
Chief
Financial Officer
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 13 April 2023 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.2240
|
316
|
|
£15.2240
|
471
|
|
£15.2240
|
702
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume
Price
|
1,489
£15.2240
|
|
e)
|
Date
of the transaction
|
2023-04-17
|
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Dr
H Barron
|
|
b)
|
Position/status
|
Non-Executive
Director
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
American
Depositary Shares ('ADSs')
ISIN: US37733W2044
|
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in ADSs following the re-investment of
dividends paid to shareholders on 13 April on ADSs held in the
Company's Deferred Annual Bonus Plan
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
$38.3200
|
309
|
|
$38.3200
|
233
|
|
$38.3200
|
369
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume
Price
|
911
$38.3200
|
|
e)
|
Date
of the transaction
|
2023-04-17
|
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Ms
D Conrad
|
|
b)
|
Position/status
|
Chief
People Officer
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 13 April 2023 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.2240
|
66
|
|
£15.2240
|
107
|
|
£15.2240
|
206
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume
Price
|
379
£15.2240
|
|
e)
|
Date
of the transaction
|
2023-04-17
|
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr
J Ford
|
|
b)
|
Position/status
|
SVP
and Group General Counsel, Legal and Compliance
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 13 April 2023 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.2240
|
79
|
|
£15.2240
|
131
|
|
£15.2240
|
200
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume
Price
|
410
£15.2240
|
|
e)
|
Date
of the transaction
|
2023-04-17
|
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Ms
S Jackson
|
|
b)
|
Position/status
|
SVP,
Global Communications and CEO Office
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 13 April 2023 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.2240
|
40
|
|
£15.2240
|
61
|
|
£15.2240
|
124
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume
Price
|
225
£15.2240
|
|
e)
|
Date
of the transaction
|
2023-04-17
|
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr
L Miels
|
|
b)
|
Position/status
|
Chief
Commercial Officer
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 13 April 2023 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.2240
|
123
|
|
£15.2240
|
224
|
|
£15.2240
|
483
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume
Price
|
830
£15.2240
|
|
e)
|
Date
of the transaction
|
2023-04-17
|
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Ms
S Ramakrishnan
|
|
b)
|
Position/status
|
Chief
Digital and Technology Officer
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
American
Depositary Shares ('ADSs')
ISIN: US37733W2044
|
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in ADSs following the re-investment of
dividends paid to shareholders on 13 April 2023 on ADSs held in the
Company's Deferred Annual Bonus Plan
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
$38.3200
|
22
|
|
$38.3200
|
97
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume
Price
|
119
$38.3200
|
|
e)
|
Date
of the transaction
|
2023-04-17
|
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr
D Redfern
|
|
b)
|
Position/status
|
President
Corporate Development
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 13 April 2023 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.2240
|
97
|
|
£15.2240
|
148
|
|
£15.2240
|
279
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume
Price
|
524
£15.2240
|
|
e)
|
Date
of the transaction
|
2023-04-17
|
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr
R Simard
|
|
b)
|
Position/status
|
President,
Global Supply Chain
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 13 April 2023 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.2240
|
73
|
|
£15.2240
|
135
|
|
£15.2240
|
224
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume
Price
|
432
£15.2240
|
|
e)
|
Date
of the transaction
|
2023-04-17
|
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr
P Thomson
|
|
b)
|
Position/status
|
President,
Global Affairs
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 13 April 2023 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.2240
|
56
|
|
£15.2240
|
93
|
|
£15.2240
|
146
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume
Price
|
295
£15.2240
|
|
e)
|
Date
of the transaction
|
2023-04-17
|
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Ms
D Waterhouse
|
|
b)
|
Position/status
|
CEO,
ViiV Healthcare and President, Global Health, GSK
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 13 April 2023 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.2240
|
116
|
|
£15.2240
|
98
|
|
£15.2240
|
357
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume
Price
|
571
£15.2240
|
|
e)
|
Date
of the transaction
|
2023-04-17
|
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr
T Wood
|
|
b)
|
Position/status
|
Chief
Scientific Officer
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 13 April 2023 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.2240
|
169
|
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the transaction
|
2023-04-17
|
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Ms
E Walmsley
|
|
b)
|
Position/status
|
Chief
Executive Officer
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
|
b)
|
Nature of
the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 13 April 2023 on Ordinary Shares held in the
Company's Performance Share Plan subject to a 2-year holding
period
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.2240
|
4,731.228
|
|
d)
|
Aggregated information
Aggregated volume
Price
|
N/A
(single transaction)
|
|
e)
|
Date
of the transaction
|
2023-04-17
|
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr
I Mackay
|
|
b)
|
Position/status
|
Chief
Financial Officer
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 13 April 2023 on Ordinary Shares held in the
Company's Performance Share Plan subject to a 2-year holding
period
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£15.2240
|
2,573.292
|
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the transaction
|
2023-04-17
|
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Dr
Hal Barron
|
|
b)
|
Position/status
|
Non-Executive
Director
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 13 April 2023
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
$37.5050
|
4
|
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the transaction
|
2023-04-17
|
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Dr
Vishal Sikka
|
|
b)
|
Position/status
|
Independent
Non-Executive Director
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 13 April 2023
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
$37.5050
|
10
|
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date
of the transaction
|
2023-04-17
|
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorised.
|
|
GSK
plc
|
|
|
(Registrant)
|
|
|
|
|
Date: April
19, 2023
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Sep 2023 to Oct 2023
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2022 to Oct 2023
